The treatment of refractory angina. The place of ranolazine

O.A. Yepanchintseva, O.J. Zharinov , I.V. Shklianka, A.V. Khokhlov

References

1. Bennett N.M., Iyer V., Arndt T.L. et al. Ranolazine refractory angina registry: 1-year results // Crit. Pathw.Cardiol.– 2014.– Vol. 13 (3).– P. 96–98.
2. Сarbone F., Montecucco F., Mach F. Update on evidence for treatment with ranolazine in stable angina // Swiss. Med. Wkly.–2013.– Vol. 143.– P. 1–8.
3. Davies A., Fox K., Galassi A.R. et al. Management of refractory angina: an update // Eur. Heart. J.– 2021.– Vol. 42 (Issue 31).– P. 269–283.  doi: 10.1093/eurheartj/ehaa820.
4. Greenea R.S., Rangela R.M., Edwardsa K.L. et al. Ranolazine for the treatment of refractory angina in a veterans population // Cardiovasc. Revasc. Med.– 2012.– Vol. 13 (2).– P. 141.e1–141.e5. doi: 10.1016/j.carrev.2011.06.001.
5. Henry T.D., Satran D., Hodges J.S. et al. Long-term survival in patients with refractory angina // Eur. Heart. J.– 2013.– Vol. 34 (34).– P. 2683–2688. doi: 10.1093/eurheartj/eht165.
6. Knuuti J., Wijns W., Saraste A. et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes // Eur. Heart J.– 2020.– Vol. 41.– P. 407–477. doi: 10.1093/eurheartj/ehz425.
7. Makowski M., Makowska J.S., Zielińska M. Refractory angina-unsolved problem // Cardiol. Clin.– 2020.– Vol. 38 (4).– P. 629–637. doi: 10.1016/j.ccl.2020.07.009.
8. Maron D.J., Hochman J.S., Reynolds H.R. et al. ISCHEMIA Research Group. Initial invasive or conservative strategy for stable coronary disease // New Engl. J. Med.– 2020.– Vol. 382.– P. 1395–1407. doi: 10.1056/NEJMoa1915922.
9. Mukherjee D. Management of refractory angina in the contemporary era // Eur. Heart. J.– 2013.– Vol. 34.– P. 2655–2657. doi:10.1093/eurheartj/eht190.
10. Navarese E.P., Lansky A.J., Kereiakes D.J. et al. Cardiacmortality in patients randomised to elective coronary revascularisation plusmedical therapy ormedical therapy alone: a systematic review andmeta-analysis // Eur. Heart. J.– 2021.– Vol. 00.– P. 1–14. doi: 101093/eurheartj/ehab246.
11. Sardella G., Stella P., Chiarito M. et al. Clinical outcomes with reservoir-based polymer-free amphilimus-elutingstents in real-world patients according to diabetes mellitus and complexity: The INVESTIG8 registry // Catheter. Cardiovasc. Interv.– 2018.– Vol. 91.– P. 884–891. doi: 10.1002/ccd.27187.
12. Storey K.M., Wang J., Garberich R.F. et al. Long-Term (3 Years) Outcomes of Ranolazine Therapy for Refractory Angina Pectoris (From the Ranolazine Refractory Registry) // Am. J. Cardiol.– 2020.– Vol. 129.– P. 1–4. doi: 10.1016/j.amjcard.2020.05.020.